ConvaTec appoints Dr Ros Rivaz as to its Board as Non-Executive Director

– UK, Reading – ConvaTec Group Plc (LSE:CTEC), is pleased to announce the appointment of Dr Ros Rivaz as a Non-Executive Director of the Company with immediate effect.

Dr Rivaz’ non-executive Board experience spans FTSE100, large private and not-for-profit organisations. She served as a Non-Executive Director and Chairman of the Remuneration Committee at Rexam prior to its acquisition by Ball Corporation in 2016, and currently sits on the Board of RPC Group, Computacenter, Ministry of Defence Equipment and Support and is also Vice Chair of the Council of Southampton University, amongst other roles.

Previously, Dr Rivaz held a range of senior executive management roles across major FTSE100 and international businesses. From 2011 to 2014 she was Global Chief Operating Officer of Smith & Nephew, having previously served in senior Operations, Manufacturing and Supply Chain roles at Premier Foods, Diageo, ICI, and Tate & Lyle.

Sir Christopher Gent, Chairman of ConvaTec, commented: “I am delighted to welcome Ros to the Board of ConvaTec. She brings exceptional and significant experience gained from a successful career across a variety of industries. Ros has a detailed understanding of the medical products and technology sector, and she will make a valuable contribution to ConvaTec. The Board looks forward to working closely with her.

As we have reshaped our shareholder base and welcomed Novo A/S as a strategic investor, we are creating a Board that reflects the future ambitions of ConvaTec. In my governance letter in the Annual Report I made it clear that the membership of the Board will in time reflect the requirements for gender diversity and that it will have a majority of independent Directors. To this end, we will appoint a further non-executive Director, and the candidates for this position will be from an all-female shortlist.”

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec’s products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>